M. Lowinski

Estimation of Drug-Target Residence Times by τ-Random Acceleration Molecular Dynamics Simulations.

R. Wade, M. Frech, M. Dreyer, 2018, Journal of chemical theory and computation.

KRAS G12C fragment screening renders new binding pockets

M. Mathieu, L. Debussche, M. Lowinski, 2021, Small GTPases.

UMP kinase from Streptococcus pneumoniae: evidence for co-operative ATP binding and allosteric regulation.

P. Ferrari, M. Lowinski, F. Fassy, 2004, The Biochemical journal.

Abstract 4648: In vitro characterization of spiro-oxindole-based modulators of the MDM2-p53 interaction and their interspecies selectivity.

Shaomeng Wang, J. Watters, C. García-echeverría, 2012 .

Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844).

A. Rak, F. Vallée, M. Lowinski, 2016, Journal of medicinal chemistry.

Determination of oenothein B as the active 5-alpha-reductase-inhibiting principle of the folk medicine Epilobium parviflorum.

G. Teutsch, M. Lowinski, P. Devaux, 1996, Journal of natural products.

Accurate absolute free energies for ligand–protein binding based on non-equilibrium approaches

Klaus Gerwert, Jürgen Schlitter, Djordje Musil, 2019, Communications Chemistry.

The use of virtual screening and differential scanning fluorimetry for the rapid identification of fragments active against MEK1.

Maryse Lowinski, A. Rak, F. Vallée, 2013, Bioorganic & medicinal chemistry letters.